Back to Search
Start Over
Ashvattha Therapeutics to Present Preclinical Data at the CMSC and SNMMI Annual Meetings
- Source :
- GlobeNewswire. May 23, 2024
- Publication Year :
- 2024
-
Abstract
- Presentations highlight the therapeutic potential of Ashvattha's novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE preclinical model CSF1R dendranib (H74DS3M8) [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.794890150